Schon M, Boeknck WH: Psoriasis. NEJM. 2005, 352: 1899-1912. 10.1056/NEJMra041320.
Article
CAS
PubMed
Google Scholar
Gladman DD: Psoriatic arthritis. Rheum Dis Clin North Am. 1998, 24: 829-44. 10.1016/S0889-857X(05)70044-2.
Article
CAS
PubMed
Google Scholar
Lawrence RC, Hochberg MC, Kelsey JL, et al: Estimate of the prevalence of selected arthritis and musculoskeletal diseases in the United States. J Rheumatol. 1989, 16: 427-41.
CAS
PubMed
Google Scholar
Gladman DD, Farewell VT, Nadeau C: Clinical indicators of progression in psoriatic arthritis: multivariate relative risk mode. J Rheumatol. 1995, 22: 675-9.
CAS
PubMed
Google Scholar
Little H, Harvie JN, Lester RS: Psoriatic arthritis in severe psoriasis. Can Med Assoc J. 1975, 112: 317-9.
PubMed Central
CAS
PubMed
Google Scholar
Leonard DG, O'Duffy JD, Rogers RS: Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc. 1978, 53: 511-8.
CAS
PubMed
Google Scholar
Elkayam O, Ophir J, Yaron M, Caspi D: Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol. 2000, 19: 301-5. 10.1007/s100670070005.
Article
CAS
PubMed
Google Scholar
Gladman DD, Anhorn KAB, Schachter RK, Mervart H: HLA antigens in psoriatic arthritis. J Rheumatol. 1986, 13: 586-92.
CAS
PubMed
Google Scholar
Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK: Psoriatic arthritis – an analysis of 220 patients. Quart J Med. 1987, 62: 127-41.
CAS
PubMed
Google Scholar
Espinoza LR: Psoriatic arthritis: further epidemiologic and genetic consideration. Psoriatic arthritis. Edited by: Gerber LH, Espinoza. 1985, Grune & Stratton, Orlando Florida, 9-32.
Google Scholar
Sakkas LI, Loqueman N, Bird H, Vaughan RW, Welsh KI, Panayi GS: HLA class II and T cell receptor gene polymorphisms in psoriatic arthritis and psoriasis. J Rheumatol. 1990, 17: 1487-90.
CAS
PubMed
Google Scholar
Eastmon CJ: Psoriatic arthritis. Genetics and HLA antigens. Baillieres Clin Rheumatol. 1994, 8: 263-76.
Article
Google Scholar
Tomfohrde J, Silverman A, Barnes R, et al: Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 1994, 264: 1141-5.
Article
CAS
PubMed
Google Scholar
Matthews D, Fry L, Powels A, et al: Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet. 1996, 13: 231-3. 10.1038/ng1096-231.
Article
Google Scholar
Burden A, Javed S, Bailey M, et al: Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol. 1998, 110: 958-60. 10.1046/j.1523-1747.1998.00213.x.
Article
CAS
PubMed
Google Scholar
Veal CD, Clough RL, Barber RC, et al: Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet. 2001, 38: 7-13. 10.1136/jmg.38.1.7.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hohler T, Kruger A, Schneider PM, et al: A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol. 1997, 109: 562-5. 10.1111/1523-1747.ep12337469.
Article
CAS
PubMed
Google Scholar
Balding J, Kane D, Lingstone W, Mynett-Johnson L, Bresnihan B, Smith O, FitzGerald O: Cytokine Gene Polymorphisms: Associations with Psoriatic Arthritis Susceptibility and Severity. Arth & Rheum. 2003, 48: 1408-1413. 10.1002/art.10935.
Article
CAS
Google Scholar
Rahman P, Siannis F, Butt C, Farewell V, Peddle L, Pellet F, Gladman D: Meta-Analysis of TNF-Alpha Polymorphisms in Caucasian Psoriatic Arthritis Populations. Ann Rheum Dis. 2005, 64 (SIII): 325-
Google Scholar
Gonzalez S, Martinez-Borra J, Lopez-Vazquez A, et al: MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. J Rheumatol. 2002, 29: 973-8.
CAS
PubMed
Google Scholar
Vasey FB: Etiology and pathogenesis of psoriatic arthritis. Psoriatic arthritis. Edited by: Gerber LH, Espinoza. 1985, Grune & Stratton, Orlando Florida, 45-57.
Google Scholar
Vasey FB, Deitz C, Fenske NA, et al: Possible involvement of group A streptococci in the pathogenesis of psoriatic arthritis. J Rheumatol. 1982, 9: 719-22.
CAS
PubMed
Google Scholar
Njobvu P, McGill P: Psoriatic arthritis and human immunodeficiency virus infection in Zambia. J Rheumatol. 2000, 27: 1699-702.
CAS
PubMed
Google Scholar
Taglione EV, Martini ML, Galluzzo P, et al: Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol. 1999, 26: 370-2.
CAS
PubMed
Google Scholar
Panayi G: Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol. 1994, 8: 419-27.
Article
CAS
PubMed
Google Scholar
Veale DJ, Barnes L, Rogers S, Fitzgerald O: Immunohistochemical markers for arthritis in psoriasis. Ann Rheum Dis. 1994, 53: 450-4.
Article
PubMed Central
CAS
PubMed
Google Scholar
Costello PJ, Winchester RJ, Curran SA, et al: Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. J Immunol. 2001, 166: 2878-86.
Article
CAS
PubMed
Google Scholar
Laloux L, Voisin MC, Allain J, et al: Immunohistological study of enthesis in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001, 60: 316-21. 10.1136/ard.60.4.316.
Article
PubMed Central
CAS
PubMed
Google Scholar
Tassiulas I, Duncan SR, Centola M, et al: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol. 1999, 60: 479-91. 10.1016/S0198-8859(99)00034-8.
Article
CAS
PubMed
Google Scholar
Ritchlin C, Haas-Smith SA, Hicks D, et al: Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998, 25: 1544-52.
CAS
PubMed
Google Scholar
Danning CL, Illei GG, Hitchon C, et al: Macrophage-derived cytokine and nuclear factor kappa B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000, 43: 1244-56. 10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2.
Article
CAS
PubMed
Google Scholar
Saklatvala J: Tumor necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986, 322: 547-9. 10.1038/322547a0.
Article
CAS
PubMed
Google Scholar
Bertolini DR, Nedwin GE, Bringman TS, et al: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature. 1986, 319: 516-8. 10.1038/319516a0.
Article
CAS
PubMed
Google Scholar
Ettehadi P, Greaves MW, Wallach D, et al: Elevated tumor necrosis factor alpha biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994, 96: 146-51.
Article
PubMed Central
CAS
PubMed
Google Scholar
Fearon U, Reece R, Smith J, et al: Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann N Y Acad Sci. 1999, 878: 619-21.
Article
CAS
PubMed
Google Scholar
Pitzalis C, Cauli A, Pipitone N, et al: Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum. 1996, 39: 137-45.
Article
CAS
PubMed
Google Scholar
McHugh NJ, Balachrishnan C, Jones SM: Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology. 2003, 42: 778-83. 10.1093/rheumatology/keg217.
Article
CAS
PubMed
Google Scholar
Resnick D, Niwayama G: Psoriatic arthritis. Diagnosis of bone joint disorders. 1981, WB Saunder Co, Philadelphia, 1103-29.
Google Scholar
Gladman DD, Shuckett R, Russell ML, et al: Psoriatic arthritis – an analysis of 220 patients. Quart J Med. 1987, 62: 127-41.
CAS
PubMed
Google Scholar
Jones SM, Armas JB, Cohen MG, et al: Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994, 33: 834-9.
Article
CAS
PubMed
Google Scholar
Kane D, Stafford L, Bresnihan B, Fitzgerald O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology. 2003 Oct 1,
Pringle F: A multidisciplinary approach to psoriatic arthropathy. Community Nurse. 1999, 5: 21-2.
CAS
PubMed
Google Scholar
Gladman DD, Farewell VT, Wong K, Husted J: Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998, 41: 1103-10. 10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N.
Article
CAS
PubMed
Google Scholar
Christophers E, Mrowietz U: Psoriasis. Fitzpatrick's Dermatology in General Medicine. Edited by: Freedberg IM, Eisen AZ, Wolff K. 1999, McGraw Hill, New York, 495-521. 5
Google Scholar
Black RL, O'Brian WM, Van Scott EJ, et al: Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA. 1964, 189: 141-5.
Article
Google Scholar
Willkens RF, Williams HJ, Ward JR, et al: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984, 27: 376-81.
Article
CAS
PubMed
Google Scholar
Marquerie L, Flipo RM, Grardel B, et al: Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint bone spine. 2002, 69: 275-81. 10.1016/S1297-319X(02)00396-2.
Article
Google Scholar
Spadaro A, Taccari E, Mohtadi B, et al: Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs. Clin Exp Rheumatol. 1997, 15: 609-14.
CAS
PubMed
Google Scholar
Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk F, Mease P, for the Treatment of Psoriatic Arthritis Study Group: Efficacy and Safety of Leflunomide in the Treatment of Psoriatic Arthritis and Psoriasis: A Multinational, Double Blind, Randomized, Placebo Controlled Clinical Trial. Arthritis Rheum. 2004, 50: 1939-50. 10.1002/art.20253.
Article
CAS
PubMed
Google Scholar
Clegg DO, Reda DJ, Mejias E, et al: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996, 39: 2013-20.
Article
CAS
PubMed
Google Scholar
Ellis CN, Fradin MS, Messana JM, et al: Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 1991, 324: 277-84.
Article
CAS
PubMed
Google Scholar
Braun J, Sieper J: Role of novel biological therapies in psoriatic arthritis. Biodrugs. 2003, 17: 187-99.
Article
CAS
PubMed
Google Scholar
Kavanaugh A, Cohen S, Cush J: The evolving use of TNF inhibitors in rheumatoid arthritis. J Rheumatol. 2004, 31: 1881-4.
PubMed
Google Scholar
Moreland LW, Cohen SB, Baumgartner SW, et al: Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001, 28: 1238-44.
CAS
PubMed
Google Scholar
Bondeson J, Maini RN: Tumor necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int J Clin Pract. 2001, 55: 211-16.
CAS
PubMed
Google Scholar
Mease P, Goffe BS, Metz J, et al: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000, 356: 385-90. 10.1016/S0140-6736(00)02530-7.
Article
CAS
PubMed
Google Scholar
Mease P, Kivitz A, Burch F, et al: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial (abstract). Arthritis Rheum. 2001, 44 (suppl 9): S90-
Google Scholar
Clegg DO, Reda DJ, Mejias E, et al: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum. 1996, 39: 2013-20.
Article
CAS
PubMed
Google Scholar
Felson DT, Andersen JJ, Boers M, et al: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 727-35.
Article
CAS
PubMed
Google Scholar
Mease PJ, Goffe BS, Metz J, et al: Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis (poster). Ann Rheum Dis. 2001, 60 (Suppl 1): 146-
Google Scholar
Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W: Etanercept Treatment of Psoriatic Arthritis: Safety, Efficacy, and Effect on Disease Progression. Arthritis Rheum. 2004, 50: 2264-72. 10.1002/art.20335.
Article
CAS
PubMed
Google Scholar
Salvarani C, Cantini F, Olivieri I, et al: Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. 2003, 49: 541-5. 10.1002/art.11201.
Article
CAS
PubMed
Google Scholar
Ogilvie AL, Antoni C, Dechant C, et al: Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001, 144: 587-9. 10.1046/j.1365-2133.2001.04089.x.
Article
CAS
PubMed
Google Scholar
Van den Bosch F, Kruithof E, Baeten D, et al: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000, 59: 428-33. 10.1136/ard.59.6.428.
Article
PubMed Central
CAS
PubMed
Google Scholar
Antoni C, Kavanaugh A, Kirkham B, et al: The one-year results of the infliximab multinational psoriatic arthritis controlled trial. Arthritis Rheum. 2003, ACR abstract S604
Google Scholar
Van den Bosch F, Kruithof E, Baeten D, et al: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum. 2002, 46: 755-65. 10.1002/art.511.
Article
CAS
PubMed
Google Scholar
Antoni , Krueger , De Vlam, Birbara , Beutler , Guzzo , Zhou , Dooley , Kavanaugh : Infliximab Improves Signs and Symptoms of Psoriatic Arthritis: Results of the IMPACT 2 Trial. Ann Rheum Dis. 2005, 000: 1-8.
Google Scholar
van der Heijde D, Kavanaugh A, Beutler A, Guzzo C, Zhou B, Dooley L, Antoni CE, Krueger GG, Gladman D: Infliximab Inhibits Progression of Radiographic Damage in Patients With Active Psoriatic Arthritis: Results for Impact 2 Trial. Ann Rheum Dis. 2005, 64 (SIII): 109-
Google Scholar
Antoni CE, Kavanaugh A, Gladman D, Wassenberg S, Zhou B, Beutler A, Bermester G, Furst DE, Weisman M, Ebner W, Kalden JR, Smolen J, van der Heijde D: Ann Rheum Dis. 2005, 64 (SIII): 107-
Google Scholar
Mease P, Gladman D, Ritchlin C, Ruderman E, Steinfeld S, Choy E, Perdok R, Weinberg M: Adalimumab Therapy in Patients with Psoriatic Arthritis: 24-week Results of a Phase III Study. Arthritis Rheum. 2004, 4097-50
Mease PJ, Sharp JI, Ory P, Gladman DD, Ritchlin CT, Choy EH, Weinberg EH: Adalimumab Treatment Effects on Radiographic Progression of Joint Disease in Patients with Psoriatic Arthritis: Result from ADEPT. Ann Rheum Dis. 2005, 64 (SIII): 320-
Google Scholar
Weinberg JM: An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther. 2003, 25: 2487-505. 10.1016/S0149-2918(03)80313-2.
Article
CAS
PubMed
Google Scholar
Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001, 345: 248-55. 10.1056/NEJM200107263450403.
Article
CAS
PubMed
Google Scholar
Kraan MC, van Kuijk AWR, Dinant HJ, et al: Alefacept treatment in psoriatic arthritis. Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002, 46: 2776-84. 10.1002/art.10543.
Article
CAS
PubMed
Google Scholar
Mease P, Gladman D, Keystone E: Efficacy of Alefacept in Combination with Methotrexate in the Treatment of Psoriatic Arthritis. Ann Rheum Dis. 2005, 64 (SIII): 324-
Google Scholar
Gladman D, Mease P, Keystone E: Safety of Alefacept in Combination with Methotrexate in the Treatment of Psoriatic Arthritis. Ann Rheum Dis. 2005, 64 (SIII): 324-325.
Google Scholar
Leonardi , Papp , Gordon , Menter , Feldman , Cato , Walicke , Compton , Gottlieb : Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol. 2005, 52: 425-433. 10.1016/j.jaad.2004.09.029.
Article
PubMed
Google Scholar
Menter , Gordon , Carey , Hamilton , Glazer , Caro , Li , Gulliver : Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients with Moderate to Severe Plaque Psoriasis. Arch Dermatol. 2005, 141: 31-38. 10.1001/archderm.141.1.31.
Article
CAS
PubMed
Google Scholar
[http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=7287]
Barker JN, Jones ML, Mitra RS, et al: Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol. 1991, 139: 869-876.
PubMed Central
CAS
PubMed
Google Scholar
Singri P, West DP, Gordon KB: Patterns of cytokine production in psoriatic synovium. Arch Dermatol. 2002, 138: 657-663. 10.1001/archderm.138.5.657.
CAS
PubMed
Google Scholar
Bresnihan B, Cunnane G: Interleukin-1 receptor antagonist. Rheum Dis Clin North Am. 1998, 24: 187-199. 10.1016/S0889-857X(05)70029-6.
Article
Google Scholar
Ritchlin C, Haas-Smith SA, Hicks D, et al: Patterns of cytokine production in psoriatic synovium. J Rheum. 1998, 25: 1544-1552.
CAS
PubMed
Google Scholar
Reich K, Garbe C, Blaschke V, et al: Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol. 2001, 116: 319-329. 10.1046/j.1523-1747.2001.01248.x.
Article
CAS
PubMed
Google Scholar
McInnes IB, Illei GG, Danning CL, et al: IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol. 2001, 167: 2161-2168.
Article
Google Scholar
Trepicchio WL, Ozawa M, Walter IB, et al: Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999, 104: 1527-1537.
Article
PubMed Central
CAS
PubMed
Google Scholar
Krueger JG, Walters IB, Miyazawa M, et al: Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol. 2000, 43: 448-458. 10.1067/mjd.2000.106515.
Article
CAS
PubMed
Google Scholar
Utset TO, Auger JA, Peace D, et al: Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheum. 2002, 29: 1907-1913.
CAS
PubMed
Google Scholar
Abrams JR, Kelley SL, Hayes E, et al: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-Immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000, 192: 681-693. 10.1084/jem.192.5.681.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gottlieb A, Kang S, Linden K, Lebwohl M, Menter A, Abdulghani A, Goldfrab M, Cheiffo N, Tortoritis : Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Imm. 2004, 111: 28-37. 10.1016/j.clim.2004.01.006.
Article
CAS
Google Scholar